Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2024-12-05 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
独立董事提名人声明与承诺（辛金国）
Board/Management Information Classification · 100% confidence The document is a formal statement and commitment regarding the nomination of an independent director candidate for the company's board. It details the qualifications, legal compliance, independence criteria, and absence of adverse records for the nominee. There is no financial data, no report of financial results, no mention of a meeting agenda or voting results, and no indication of a report publication or regulatory filing. The content is focused on board/management information, specifically about a nomination to the board of directors. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report but a substantive statement about management nomination.
2024-12-05 Chinese
独立董事提名人声明与承诺（王桂华）
Board/Management Information Classification · 95% confidence The document is a formal statement from the board of Kunming Pharmaceutical Corporation nominating an independent director candidate, Wang Guihua, for the company's 11th board of directors. It details the candidate's qualifications, compliance with relevant laws and regulations, independence criteria, and absence of adverse records. The content focuses on board/management information, specifically the nomination and qualifications of a board member. There is no financial data, earnings information, or report publication mentioned. The document is not an announcement of voting results or a proxy solicitation but a declaration related to board management. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is short and focused on management nomination, supporting this classification with high confidence.
2024-12-05 Chinese
昆药集团十届三十六次董事会决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of resolutions passed at a board meeting, specifically about the election of a new board of directors and amendments to the company's articles of association. It includes voting results and mentions that these resolutions will be submitted to the shareholders' meeting for approval. There is no detailed financial data, audit information, or report content. The document is not a full report but an announcement of board decisions and nominations. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2024-12-05 Chinese
昆药集团关于全资子公司获得药品补充申请批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the approval of a supplemental drug application by its wholly-owned subsidiary. It details the approval of an updated drug label for colchicine tablets to include a new pediatric indication. The document includes regulatory references, drug details, and impact statements but does not contain financial statements, earnings data, or detailed management analysis. It is a regulatory announcement about a product approval, not a financial report or management discussion. The document length is short (1677 characters), and it is an announcement of a regulatory approval rather than a report or presentation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-11-28 Chinese
昆药集团关于获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the approval of a clinical trial for a new drug by the National Medical Products Administration. It details the drug's basic information, research background, and potential impact on the company. The document is relatively short (1543 characters) and serves as a regulatory announcement about a clinical trial approval, not a financial report or detailed management discussion. It does not contain financial statements, earnings data, or detailed management analysis. It is not a report publication announcement since it does not mention the release or availability of a report. The content fits best under Regulatory Filings (RNS) as it is a general regulatory announcement about drug trial approval and related company disclosures.
2024-11-22 Chinese
昆药集团关于对外担保的进展公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the progress of external guarantees provided by Kunming Pharmaceutical Group Co., Ltd. It includes specifics about the guarantee amounts, the companies involved, financial data of the guaranteed subsidiaries, and board opinions on the guarantees. The document is not a financial report, earnings release, or management discussion but rather a regulatory announcement about financing guarantees. It does not fit into categories like Annual Report, Interim Report, or Capital/Financing Update directly, as it focuses on guarantee disclosures. It is not a short announcement about a report publication but a substantive disclosure. Therefore, it best fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2024-11-21 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.